Table 2.
Multivariable model of predictor and cardiovascular event rates, 1987–2010
| Predictor | Rate ratio | 95 % CI | P Value |
|---|---|---|---|
| Age per 10 years | 1.63 | 1.421, 1.88 | <0.0001 |
| Male sex | 1.56 | 1.01, 2.67 | 0.046 |
| Year before 1993 | 1.64 | 0.99, 2.63 | 0.053 |
| Mean systolic blood pressurea | 1.17 | 1.02, 1.35 | 0.022 |
| Mean serum cholesterola | 1.04 | 1.01, 1.08 | 0.018 |
| Diabetes mellitus | 1.52 | 0.99, 2.33 | 0.057 |
| SELENA-SLEDAI | 1.05 | 1.00, 1.11 | 0.062 |
| Anti-dsDNA | 1.56 | 1.05, 2.31 | 0.026 |
| Serum creatinine, mg/dL | |||
| - <1.0 | 1.00 | Referent | Referent |
| - 1.0–1.19 | 1.64 | 1.07, 2.50 | 0.023 |
| - ≥1.2 | 1.15 | 0.72, 1.85 | 0.56 |
| Low hematocrit | 1.18 | 0.82, 1.69 | 0.38 |
| History of hemolytic anemia | 1.28 | 0.79, 2.09 | 0.32 |
| History of lupus anticoagulant | 1.74 | 1.22, 2.47 | 0.0021 |
| Current corticosteroid dose, mg/day | |||
| - 0 | 1.00 | Referent | Referent |
| - 1–9 | 1.01 | 0.63, 1.60 | 0.98 |
| - 10–19 | 1.47 | 0.90, 2.38 | 0.12 |
| - ≥20 | 2.54 | 1.44, 4.48 | 0.0013 |
| Hydroxychloroquine (in past six consecutive months) | 0.77 | 0.54, 1.12 | 0.17 |
Abbreviations: CI, confidence interval; dsDNA, double stranded DNA; SELENA, safety of estrogens in lupus erythematosus national assessment; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index instrument score
aMean during previous cohort participation
Reprinted from Magder and Petri [23••], with permission from Oxford University Press